Biomerica, Inc. (NASDAQ:BMRA) Sees Significant Increase in Short Interest

Biomerica, Inc. (NASDAQ:BMRAGet Free Report) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 419,000 shares, an increase of 64.6% from the January 31st total of 254,500 shares. Based on an average trading volume of 7,750,000 shares, the short-interest ratio is currently 0.1 days.

Biomerica Stock Down 3.1 %

Shares of BMRA stock traded down $0.02 on Monday, reaching $0.71. The stock had a trading volume of 300,900 shares, compared to its average volume of 2,208,857. Biomerica has a 12 month low of $0.24 and a 12 month high of $1.27. The firm has a market capitalization of $13.06 million, a price-to-earnings ratio of -2.09 and a beta of -0.98. The firm’s 50-day moving average is $0.55 and its two-hundred day moving average is $0.42.

Biomerica (NASDAQ:BMRAGet Free Report) last released its quarterly earnings data on Tuesday, January 14th. The company reported ($0.06) earnings per share (EPS) for the quarter. Biomerica had a negative net margin of 100.52% and a negative return on equity of 90.19%.

Institutional Investors Weigh In On Biomerica

An institutional investor recently raised its position in Biomerica stock. Granahan Investment Management LLC grew its stake in Biomerica, Inc. (NASDAQ:BMRAFree Report) by 24.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 658,767 shares of the company’s stock after purchasing an additional 131,306 shares during the quarter. Granahan Investment Management LLC owned approximately 3.59% of Biomerica worth $198,000 as of its most recent SEC filing. Institutional investors and hedge funds own 22.28% of the company’s stock.

Biomerica Company Profile

(Get Free Report)

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.

Read More

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.